Delpacibart Etedesiran Improves the Molecular Pathology of Myotonic Dystrophy Type 1 in the Phase 1/2 MARINA&#174; Study.

delpacibart etedesiran (AOC 1001) - Avidity Biosci

AOC-Pompe Disease - Eli Lilly, Avidity Biosci

http://www.ncbi.nlm.nih.gov/pubmed/41821312

Arthur A Levin; Barbora Malecova; Charles Thornton; Husam S Younis; Li-Jung Tai; Nathaniel Delos Santos; Nicholas Johnson; Qingying Meng; Rob Burke; Tanya T Kwan; W Michael Flanagan; Yiming Zhu

Mar 13, 2026